Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 140 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Purpura, Thrombocytopenic Clear all
Active, not recruiting Phase 3 Interventional

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

NCT05653349
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Ianalumab, Placebo, Corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Yuma, Arizona • Clovis, California • Fountain Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 3, 2026, 2:08 PM EDT
Completed No phase listed Observational

Association of Platelet Parameters With Bleeding Severity in Children With ITP

NCT03810352
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 20 Years
Enrollment
95 participants
Timeline
2019 – 2023
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)

NCT05757570
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Interventions
Povetacicept
Drug
Lead sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Cooper City, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

NCT04638829
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Avatrombopag Oral Tablet
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Whittier, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

NCT01444417
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura, Immune Thrombocytopenia
Interventions
Romiplostim, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
25
States / cities
Orange, California • San Diego, California • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Eltrombopag at Escalated Doses

NCT01880047
View directory record Official record
Conditions
Immune Thrombocytopenia, Platelet Disorder
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 3, 2026, 2:08 PM EDT
Recruiting Phase 1 Interventional

OM336 in Autoimmune Cytopenias

NCT07083960
View directory record Official record
Conditions
AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
Interventions
OM336
Drug
Lead sponsor
Lakefront Biotherapeutics West LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Terminated No phase listed Observational

Octaplas Adult TTP Trial

NCT01938404
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Octaplas, Standard Plasma
Biological · Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Manhasset, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02077192
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Fostamatinib Disodium
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Tucson, Arizona • Peoria, Illinois • Lafayette, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 3, 2026, 2:08 PM EDT
Completed No phase listed Observational

LENS - Long-term Eltrombopag Observational Study

NCT00643929
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Not listed
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 3, 2026, 2:08 PM EDT
Terminated Phase 1 Interventional Results available

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

NCT02009761
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
BI 655064
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 3, 2026, 2:08 PM EDT
Recruiting Phase 3 Interventional

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000
View directory record Official record
Conditions
Chronic Primary Immune Thrombocytopenia (ITP)
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Shirley, New York • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

NCT00547066
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune
Interventions
veltuzumab
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Riverdale, Georgia • Tucker, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 3, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT01129024
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Lusutrombopag
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

NCT00360685
View directory record Official record
Conditions
Mucositis, Graft-versus-host Disease
Interventions
Tac+MTX, TAC + MMF
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Not listed
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

NCT03939637
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00908037
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Year to 17 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
18
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 3, 2026, 2:08 PM EDT
Terminated No phase listed Observational

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

NCT01386723
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Discontinuation of eltrombopag
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

NCT01072162
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 3, 2026, 2:08 PM EDT
Completed No phase listed Observational

Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

NCT06665308
View directory record Official record
Conditions
Chronic Immune Thrombocytopenia, Primary Immune Thrombocytopenia, Adult Immune Thrombocytopenia
Interventions
No intervention
Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Recruiting Phase 3 Interventional

A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)

NCT07700238
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Romiplostim, Predniso(lo)ne
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Long Beach, California • Peoria, Illinois • Fredericksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 3, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

NCT02273960
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV, BMS-986004 1500 mg IV
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 3, 2026, 2:08 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04596995
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 3, 2026, 2:08 PM EDT